HASF, a PKC-ε activator with novel features for cardiomyocyte protection

Journal of Molecular and Cellular Cardiology

Volumn 69, Issue , 2014, Pages 1-3

  Miura, Tetsuji ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A1 RECEPTOR; ALDEHYDE DEHYDROGENASE ISOENZYME 2; CONNEXIN 43; CYTOKINE RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLYCOGEN SYNTHASE KINASE 3BETA; GROWTH FACTOR RECEPTOR; HYPOXIA AND AKT INDUCED STEM CELL FACTOR; PROTEIN KINASE B; PROTEIN KINASE C EPSILON; REACTIVE OXYGEN METABOLITE; STEM CELL FACTOR; UNCLASSIFIED DRUG; MEMBRANE PROTEIN;

ACUTE HEART INFARCTION; CALCIUM TRANSPORT; CELL DEATH; CELL PROTECTION; CELL SURVIVAL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EDITORIAL; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; INNER MEMBRANE; INTRACELLULAR SIGNALING; ISCHEMIC PRECONDITIONING; MEMBRANE; OUTER MEMBRANE; PRIORITY JOURNAL; PROTEIN FUNCTION; REPERFUSION INJURY; CYTOLOGY; METABOLISM; MYOCARDIAL INFARCTION; PARACRINE SIGNALING; SIGNAL TRANSDUCTION;

CYTOPROTECTION; HUMANS; MEMBRANE PROTEINS; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; PARACRINE COMMUNICATION; PROTEIN KINASE C-EPSILON; SIGNAL TRANSDUCTION;

EID: 84895423383     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.01.011     Document Type: Editorial

References (40)

1. Miura T., Miki T. Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapy. Basic Res Cardiol 2008, 103:501-513.
2. van der Spoel T.I., Jansen of Lorkeers S.J., Agostoni P., van Belle E., Gyöngyösi M., et al. Human relevance of pre-clinical studies in stem cell therapy: systematic review and meta-analysis of large animal models of ischaemic heart disease. Cardiovasc Res 2011, 91:649-658.
3. Haider K.H., Ashraf M. Preconditioning approach in stem cell therapy for the treatment of infarcted heart. Prog Mol Biol Transl Sci 2012, 111:323-356.
4. Downey J.M., Davis A.M., Cohen M.V. Signaling pathways in ischemic preconditioning. Heart Fail Rev 2007, 12:181-188.
5. Murphy E., Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev 2008, 88:581-609.
6. Garcia-Dorado D., Agullo L., Sartorio C.L., Ruiz-Meana M. Myocardial protection against reperfusion injury: the cGMP pathway. Thromb Heamost 2009, 101:645-42.
7. Miura T., Tanno M., Sato T. Mitochondrial kinase signaling pathways in myocardial protection from ischemia/reperfusion-induced necrosis. Cardiovasc Res 2010, 88:7-15.
8. Kuno A., Critz S.D., Cui L., Solodushko V., Yang X.M., Krahn T., et al. Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J Mol Cell Cardiol 2007, 43:262-271.
9. Miura T., Miki T., Yano T. Role of the gap junction in ischemic preconditioning in the heart. Am J Physiol Heart Circ Physiol 2010, 298:H1115-H1125.
10. Clarke S.J., Khaliulin I., Das M., Parker J.E., Heesom K.J., Halestrap A.P. Inhibition of mitochondrial permeability transition pore opening by ischemic preconditioning is probably mediated by reduction of oxidative stress rather than mitochondrial protein phosphorylation. Circ Res 2008, 102:1082-1090.
11. Chen C.-H., Sun L., Mochly-Rosen D. Mitochondrial aldehyde dehydrogenase and cardiac diseases. Cardiovasc Res 2010, 88:51-57.
12. Baines C.P., Zhang J., Wang G.W., Zheng Y.T., Xiu J.X., Cardwell E.M., et al. Mitochondrial PKCepsilon and MAPK form signaling modules in the murine heart: enhanced mitochondrial PKCepsilon-MAPK interactions and differential MAPK activation in PKCepsilon-induced cardioprotection. Circ Res 2002, 90:390-397.
13. Baines C.P., Song C.X., Zheng Y.T., Wang G.W., Zhang J., Wang O.L., et al. Protein kinase C-epsilon interacts with and inhibits the permeability transition pore in cardiac mitochondria. Circ Res 2003, 92:873-880.
14. Budas G.R., Churchill E.N., Disatnik M.H., Sun L., Mochly-Rosen D. Mitochondrial import of PKCepsilon is mediated by HSP90: a role in cardioprotection from ischaemia and reperfusion injury. Cardiovasc Res 2010, 88:83-92.
15. Harner M., Körner C., Walther D., Mokranjac D., Kaesmacher J., Welsch U., et al. The mitochondrial contact site complex, a determinant of mitochondrial architecture. EMBO J 2011, 30:4356-4370.
16. Miura T., Tanno M. The mPTP and its regulatory proteins: final common targets of signaling pathways for protection against necrosis. Cardiovasc Res 2012, 94:181-189.
17. Juhaszova M., Zorov D.B., Yaniv Y., Nuss H.B., Wang S., Sollott S.J. Role of glycogen synthase kinase-3beta in cardioprotection. Circ Res 2009, 104:1240-1252.
18. Chen C.H., Budas G.R., Churchill E.N., Disatnik M.H., Hurley T.D., Mochly-Rosen D. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science 2008, 321:1493-1495.
19. Miki T., Miura T., Hotta H., Tanno M., Yano T., Sato T., et al. Endoplasmic reticulum stress in diabetic hearts abolishes erythropoietin-induced myocardial protection by impairment of phospho-glycogen synthase kinase-3beta-mediated suppression of mitochondrial permeability transition. Diabetes 2009, 58:2863-2872.
20. +-ATPase. Free Radic Biol Med 1996, 20:215-223.
21. Kristal B.S., Park B.K., Yu B.P. 4-Hydroxyhexenal is a potent inducer of the mitochondrial permeability transition. J Biol Chem 1996, 271:6033-6038.
22. Itoh T., Kouzu H., Miki T., Tanno M., Kuno A., Sato T., et al. Cytoprotective regulation of the mitochondrial permeability transition pore is impaired in type 2 diabetic Goto-Kakizaki rat hearts. J Mol Cell Cardiol 2012, 53:870-879.
23. Miura T., Tanno M. Mitochondria and GSK-3β in cardioprotection against ischemia/reperfusion injury. Cardiovasc Drug Ther 2010, 24:255-263.
24. ATP channel. J Mol Cell Cardiol 2010, 49:762-770.
25. Ferreira J.C., Brum P.C., Mochly-Rosen D. βIIPKC and εPKC isozymes as potential pharmacological targets in cardiac hypertrophy and heart failure. J Mol Cell Cardiol 2011, 51:479-484.
26. Miki T., Miura T., Tsuchida A., Nakano A., Hasegawa T., Fukuma T., et al. Cardioprotective mechanism of ischemic preconditioning is impaired by postinfarct ventricular remodeling through angiotensin II type 1 receptor activation. Circulation 2000, 102:458-463.
27. Miki T., Miura T., Tanno M., Sakamoto J., Kuno A., Genda S., et al. Interruption of signal transduction between G protein and PKC-epsilon underlies the impaired myocardial response to ischemic preconditioning in postinfarct remodeled hearts. Mol Cell Biochem 2003, 247:185-193.
28. Hotta H., Miura T., Miki T., Togashi N., Maeda T., Kim S.J., et al. Angiotensin II type 1 receptor-mediated upregulation of calcineurin activity underlies impairment of cardioprotective signaling in diabetic hearts. Circ Res 2010, 106:129-132.
29. Whittington H.J., Harding I., Stephenson C.I., Bell R., Hausenloy D.J., Mocanu M.M., et al. Cardioprotection in the aging, diabetic heart: the loss of protective Akt signalling. Cardiovasc Res 2013, 99:694-704.
30. Ishihara M., Inoue I., Kawagoe T., Shimatani Y., Kurisu S., Hata T., et al. Ischaemic preconditioning effect of prodromal angina pectoris is lost in patients with prior myocardial infarction. Heart 2006, 92:973-974.
31. Ishihara M., Inoue I., Kawagoe T., Shimatani Y., Kurisu S., Nishioka K., et al. Diabetes mellitus prevents ischemic preconditioning in patients with a first acute anterior wall myocardial infarction. J Am Coll Cardiol 2001, 38:1007-1011.
32. Ross A.M., Gibbons R.J., Stone G.W., Kloner R.A., Alexander R.W. AMISTAD-II Investigators. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 2005, 45:1775-1780.
33. Newman M.F., Ferguson T.B., White J.A., Ambrosio G., Koglin J., Nussmeier N.A., et al. Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with coronary artery bypass grafting: the RED-CABG randomized controlled trial. JAMA 2012, 308:157-164.
34. Heusch G. Cardioprotection: chances and challenges of its translation to the clinic. Lancet 2013, 381:166-175.
35. Piot C., Croisille P., Staat P., Thibault H., Rioufol G., Mewton N., et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008, 359:473-481.
36. Huang J., Guo J., Beigi F., Hodgkinson C.P., Facundo H., Zhang Z., et al. HASF is a stem cell paracrine factor that activates PKC epsilon mediated cytoprotection. J Mol Cell Cardiol 2014, 66:157-164.
37. Beigi F., Schmeckpeper J., Pow-Anpongkul P., Payne J.A., Zhang L., Zhang Z., et al. C3orf58, a novel paracrine protein, stimulates cardiomyocyte cell-cycle progression through the PI3K-AKT-CDK7 pathway. Circ Res 2013, 113:372-380.
38. Cheng H., Woodgett J., Maamari M., Force T. Targeting GSK-3 family members in the heart: a very sharp double-edged sword. J Mol Cell Cardiol 2011, 51:607-613.
39. Beurel E., Jope R.S. The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 2006, 79:173-189.
40. Newton P.N., Messing R.O. The substrates and binding partners of protein kinase Cε. Biochem J 2010, 427:189-196.